DK1143955T3 - En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes - Google Patents

En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes

Info

Publication number: DK1143955T3
Authority: DK; Denmark
Prior art keywords: diabetes; treatment; combination; insulin; insulin sensitizers
Prior art date: 1998-12-24

Application number

DK99964313T

Other languages

English (en)

Inventor

Mark D Erion

Paul Vanpoelje

Original Assignee

Metabasis Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-24

Filing date

1999-12-22

Publication date

2005-11-14

1999-12-22 Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc

2005-11-14 Application granted granted Critical

2005-11-14 Publication of DK1143955T3 publication Critical patent/DK1143955T3/da

Links

101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 title abstract 2
101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 title abstract 2
101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 title abstract 2
101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 title abstract 2
101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 title abstract 2
229940122355 Insulin sensitizer Drugs 0.000 title abstract 2
206010012601 diabetes mellitus Diseases 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002641 glycemic effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

DK99964313T 1998-12-24 1999-12-22 En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes DK1143955T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11471898P	1998-12-24	1998-12-24

Publications (1)

Publication Number	Publication Date
DK1143955T3 true DK1143955T3 (da)	2005-11-14

Family

ID=22357016

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99964313T DK1143955T3 (da)	1998-12-24	1999-12-22	En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes

Country Status (25)

Country	Link
EP (1)	EP1143955B1 (da)
JP (1)	JP2003515523A (da)
KR (3)	KR100689943B1 (da)
CN (3)	CN101164618A (da)
AT (1)	ATE300288T1 (da)
AU (1)	AU771039B2 (da)
BR (1)	BR9917005A (da)
CA (1)	CA2354053A1 (da)
CZ (1)	CZ20012353A3 (da)
DE (1)	DE69926400T2 (da)
DK (1)	DK1143955T3 (da)
ES (1)	ES2246586T3 (da)
HK (1)	HK1046863B (da)
HU (1)	HUP0402506A3 (da)
ID (1)	ID30237A (da)
IL (2)	IL143569A0 (da)
MX (1)	MXPA01006511A (da)
NO (1)	NO20013115L (da)
NZ (1)	NZ512219A (da)
PL (1)	PL352756A1 (da)
PT (1)	PT1143955E (da)
RU (2)	RU2227749C2 (da)
SK (1)	SK9172001A3 (da)
WO (1)	WO2000038666A2 (da)
ZA (1)	ZA200105016B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6452098A (en)	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en)	1998-03-06	2001-11-06	Metabasis Therapeutics, Inc.	Prodrugs phosphorus-containing compounds
DE69910045T2 (de)	1998-09-09	2004-04-22	Metabasis Therapeutics Inc., San Diego	Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
AU784370B2 (en)	1999-12-22	2006-03-23	Metabasis Therapeutics, Inc.	Novel bisamidate phosphonate prodrugs
MXPA02008722A (es)	2000-03-08	2004-05-05	Metabasis Therapeutics Inc	Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0301830A3 (en) *	2000-07-06	2007-10-29	Metabasis Therapeutics Inc	Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
CA2429426A1 (en)	2000-11-17	2002-05-23	Takeda Chemical Industries, Ltd.	Isoxazole derivatives
JP4476811B2 (ja)	2002-05-13	2010-06-09	メタバシス・セラピューティクス・インコーポレイテッド	Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
JP4332496B2 (ja)	2002-05-13	2009-09-16	メタバシス・セラピューティクス・インコーポレイテッド	Ｐｍｅａおよびｐｍｐａ環生成合成
AU2003264256A1 (en) *	2002-09-04	2004-03-29	Dsm Ip Assets B.V.	A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
MXPA05008335A (es) *	2003-02-11	2006-05-04	Vernalis Cambridge Ltd	Compuestos de isoxazol como inhibidores de las proteinas de choque por calor.
CA2551611C (en) *	2003-12-26	2013-06-25	Kyowa Hakko Kogyo Co., Ltd.	Thiazole derivatives for treating or preventing parkinson's disease
KR20070053764A (ko) *	2004-08-18	2007-05-25	메타베이시스 테라퓨틱스, 인크.	프럭토스 1,6-비스포스파타제의 신규한 티아졸 억제제들
TW200633720A (en) *	2004-12-13	2006-10-01	Sankyo Co	Medicinal composition for diabetic
TW200633702A (en) *	2004-12-15	2006-10-01	Sankyo Co	Medicinal composition containing fbpase inhibitor
US20090227493A1 (en) *	2005-05-27	2009-09-10	Daiichi Sankyo Company, Limited	Combined drug for treating diabetes
EP1894930A4 (en)	2005-06-23	2010-06-23	Kyowa Hakko Kirin Co Ltd	THIAZOLE DERIVATIVE
EP2089017A2 (en)	2006-11-02	2009-08-19	Aestus Therapeutics, Inc.	Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
CN103665043B (zh)	2012-08-30	2017-11-10	江苏豪森药业集团有限公司	一种替诺福韦前药及其在医药上的应用
US9631825B2 (en)	2012-12-18	2017-04-25	Nortek Air Solutions, Llc	Air filter assembly
WO2015123352A1 (en)	2014-02-13	2015-08-20	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
WO2016003812A1 (en)	2014-07-02	2016-01-07	Ligand Pharmaceuticals, Inc.	Prodrug compounds and uses therof
CN105481896A (zh) *	2015-12-03	2016-04-13	浙江大学	一种地马格列的制备方法
CN113416739B (zh) *	2021-06-24	2022-04-19	黑龙江八一农垦大学	鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4968790A (en) *	1988-08-12	1990-11-06	American Cyanamid Company	Antidiabetic phosphates
JPH03157377A (ja) *	1988-11-18	1991-07-05	Takeda Chem Ind Ltd	チオ尿素誘導体及びａｇｅ生成阻害剤
DE69014562T2 (de) *	1989-01-24	1995-06-22	Gensia Pharma	Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) *	1997-02-19	1999-01-12	Warner-Lambert Company	Sulfonylurea-glitazone combinations for diabetes
WO1998039342A1 (en) *	1997-03-07	1998-09-11	Metabasis Therapeutics, Inc.	Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) *	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel purine inhibitors of fructose-1,6-bisphosphatase
ZA981936B (en) *	1997-03-07	1999-09-06	Metabasis Therapeutics Inc	Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.

1999
- 1999-12-22 AT AT99964313T patent/ATE300288T1/de active
- 1999-12-22 ID IDW00200101612A patent/ID30237A/id unknown
- 1999-12-22 AU AU20583/00A patent/AU771039B2/en not_active Ceased
- 1999-12-22 ES ES99964313T patent/ES2246586T3/es not_active Expired - Lifetime
- 1999-12-22 DK DK99964313T patent/DK1143955T3/da active
- 1999-12-22 RU RU2001120726/15A patent/RU2227749C2/ru not_active IP Right Cessation
- 1999-12-22 CN CNA2007101628889A patent/CN101164618A/zh active Pending
- 1999-12-22 CN CNA2005100806150A patent/CN1714866A/zh active Pending
- 1999-12-22 HK HK02108475.5A patent/HK1046863B/zh not_active IP Right Cessation
- 1999-12-22 EP EP99964313A patent/EP1143955B1/en not_active Expired - Lifetime
- 1999-12-22 BR BR9917005-1A patent/BR9917005A/pt not_active Application Discontinuation
- 1999-12-22 HU HU0402506A patent/HUP0402506A3/hu active IP Right Revival
- 1999-12-22 IL IL14356999A patent/IL143569A0/xx active IP Right Grant
- 1999-12-22 SK SK917-2001A patent/SK9172001A3/sk unknown
- 1999-12-22 CA CA002354053A patent/CA2354053A1/en not_active Abandoned
- 1999-12-22 PT PT99964313T patent/PT1143955E/pt unknown
- 1999-12-22 KR KR1020017008102A patent/KR100689943B1/ko not_active Expired - Fee Related
- 1999-12-22 MX MXPA01006511A patent/MXPA01006511A/es active IP Right Grant
- 1999-12-22 PL PL99352756A patent/PL352756A1/xx not_active Application Discontinuation
- 1999-12-22 JP JP2000590620A patent/JP2003515523A/ja active Pending
- 1999-12-22 WO PCT/US1999/030713 patent/WO2000038666A2/en not_active Ceased
- 1999-12-22 NZ NZ512219A patent/NZ512219A/xx not_active IP Right Cessation
- 1999-12-22 CN CNB998163562A patent/CN100352505C/zh not_active Expired - Fee Related
- 1999-12-22 CZ CZ20012353A patent/CZ20012353A3/cs unknown
- 1999-12-22 DE DE69926400T patent/DE69926400T2/de not_active Expired - Lifetime
- 1999-12-22 KR KR1020067022095A patent/KR20060114724A/ko not_active Ceased
- 1999-12-22 KR KR1020077008649A patent/KR20070046210A/ko not_active Ceased
2001
- 2001-06-05 IL IL143569A patent/IL143569A/en not_active IP Right Cessation
- 2001-06-19 ZA ZA200105016A patent/ZA200105016B/en unknown
- 2001-06-21 NO NO20013115A patent/NO20013115L/no not_active Application Discontinuation
2003
- 2003-10-31 RU RU2003132054/14A patent/RU2003132054A/ru not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2000038666A3 (en)	2001-11-29
WO2000038666A2 (en)	2000-07-06
CN1714866A (zh)	2006-01-04
HK1046863B (zh)	2008-07-25
KR20070046210A (ko)	2007-05-02
PL352756A1 (en)	2003-09-08
IL143569A (en)	2006-06-11
HK1046863A1 (zh)	2003-01-30
CA2354053A1 (en)	2000-07-06
CN101164618A (zh)	2008-04-23
SK9172001A3 (en)	2002-04-04
RU2003132054A (ru)	2005-04-20
CZ20012353A3 (cs)	2001-12-12
IL143569A0 (en)	2002-04-21
DE69926400D1 (de)	2005-09-01
AU771039B2 (en)	2004-03-11
CN100352505C (zh)	2007-12-05
ZA200105016B (en)	2002-09-19
AU2058300A (en)	2000-07-31
DE69926400T2 (de)	2006-05-24
BR9917005A (pt)	2002-04-02
NO20013115D0 (no)	2001-06-21
KR20010099942A (ko)	2001-11-09
KR100689943B1 (ko)	2007-03-08
HUP0402506A3 (en)	2007-05-29
CN1350466A (zh)	2002-05-22
EP1143955A3 (en)	2002-08-28
ES2246586T3 (es)	2006-02-16
MXPA01006511A (es)	2004-03-19
NZ512219A (en)	2004-12-24
ATE300288T1 (de)	2005-08-15
ID30237A (id)	2001-11-15
EP1143955B1 (en)	2005-07-27
RU2227749C2 (ru)	2004-04-27
KR20060114724A (ko)	2006-11-07
JP2003515523A (ja)	2003-05-07
EP1143955A2 (en)	2001-10-17
NO20013115L (no)	2001-08-24
HUP0402506A2 (hu)	2005-04-28
PT1143955E (pt)	2005-11-30

Publication	Publication Date	Title
DK1143955T3 (da)	2005-11-14	En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
MY169308A (en)	2019-03-21	Treatment of tnf? related disorders
DE69939864D1 (de)	2008-12-18	Ppar-gamma modulatoren
DK1373215T3 (da)	2006-11-13	Gelanamycinderivater egnet til behandling af cancer
IL157821A0 (en)	2004-03-28	Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
BR0308928A (pt)	2005-01-04	Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
PT1112275E (pt)	2003-12-31	Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
DK1651161T3 (da)	2012-01-30	Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
MX2007011706A (es)	2007-12-11	Metodo para tratar quemaduras de segundo y tercer grado utilizando solucion de agua con potencial oxido reductor.
DK1426054T3 (da)	2011-12-12	Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
DK1505990T3 (da)	2011-11-21	Fremgangsmåder til behandling af hepatitis
SI1427409T1 (sl)	2009-02-28	Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
DK1694354T3 (da)	2009-10-26	Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
IL186356A0 (en)	2008-01-20	Method of treating of preventing type-2 diabetes
DE60319681D1 (de)	2008-04-24	Zytokapazität-verfahren
DE69924385D1 (de)	2005-04-28	Verwendung von angiotensin zur behandlung von krebsmetastasierung
UA35854A (uk)	2001-04-16	Спосіб лікування приховано протікаючого силікотуберкульозу